Ambrohexal Solution for Inhalation Instructions for Use
- Ambrohexal Solution for Inhalation Instructions for Use
- Indications for use
- Side effect
- Special indications when using
- Interaction with other medicinal products
- Conditions for the sale of the medicinal product
- Storage conditions
- Shelf life
- Analogues of Ambrohexal
- Prices for inhalation solution Ambroghexal
Production: LICHTENHELDT, GmbH Pharmazeutische Fabrik (Germany)
ATX code: R05CB06 (Ambroxol)
Form release: solution for inhalation
Dosage form: clear, colorless liquid
Clinical and pharmacological group: mucolytic and expectorant drug
Pharmacotherapeutic group: a means for liquefying phlegm
Active substance: ambroxol hydrochloride - 7.5 mg / ml
Auxiliary components : sodium disulfate, sodium hydroxide, propyl parahydroxybenzoate, citric acid, purified water.
Bottle of dark glass, 50 ml (1), measuring cup, cardboard tutu.
Ambrohexal is an organic compound that has expectorant, secretolitic and secretory effects. Due to the depolymerization of mucopolysaccharides contained in the sputum, associated with the breakage in the molecules of disulfide bonds, the drug helps to reduce the viscosity of sputum, normalizing the ratio of serous and mucous component, increases the motor activity of the ciliated epithelium, increases mucolytic transport (removal of pathogenic agents) and facilitates the excretion of sputum from the respiratory tract. Providing direct influence on Clark cells located in bronchioles of the lungs and alveolar pneumocytes of type II, Ambroghexal promotes the activation of surfactant (a surfactant, which prevents the alveolar depletion on expiration).
Therapeutic effect occurs 30 minutes after taking the drug. Duration of action, depending on the dose taken - 6-12 hours.
After inhalation Ambroheksalom the degree of absorption of the drug is 25-30% of the administered dose. Maximum concentration in the lungs. Disintegrates with the formation of metabolites, excreted by the kidneys (glucuronides, dibromantranilic acid).
Binding to plasma proteins is 80-90%. 90% of the drug is excreted as metabolites by the kidneys, 10% - unchanged. Because of the high connection with plasma proteins, a large initial volume of distribution and a slow redistribution from tissues to the blood, during hemodialysis and with forced diuresis, the drug does not separate.
In severe liver pathologies, Ambrohexal's clearance is reduced by 20-40%. In severe renal disorders, T1 / 2 metabolites of the drug increases.
Ambrohexal is able to penetrate into the cerebrospinal fluid, pass through the placenta and enter the breast milk.
Indications for use
- Acute and chronic pathology of the respiratory system, proceeding with impaired spitting and spitting;
- Acute bronchitis ;
- Chronic bronchitis, unspecified etiology;
- Bronchoectatic disease;
- Bronchial asthma;
- Chronic obstructive pulmonary disease (COPD);
- Bacterial pneumonia, not elsewhere classified;
- Treatment and prevention of respiratory distress syndrome.
1 milliliter - 20 drops.
Children older than 5 years and adults are prescribed inhalation 1-2 times a day (2-3 ml, 40-60 drops).
Children under 5 years of inhalation are 1-2 times a day for 2 ml (40 drops).
The procedure is carried out using an inhaler (a special device for inhalation).
From the digestive tract: abdominal pain, nausea, vomiting, diarrhea, constipation (from ≥0.1% to <1%);
Allergic reactions: skin rash, itching, hives , angioedema (from ≥ 0.1% to <1%);
Anaphylactic reactions, including anaphylactic shock (<0.01%);
Common disorders: headache, weakness, febrile state (from ≥0.1% to <1%);
Other disorders: rhinorrhea, drying of the oral mucosa and respiratory tract, dysuric disorders, exanthematous eruptions, changes in taste sensations (from ≥0.1% to <1%).
- Hypersensitivity to the components of the drug;
- I trimester of pregnancy.
Patients with increased sputum formation (fixed cilia syndrome), impaired motor function of the bronchi, exacerbation of gastric ulcer and 12-n. Guts, in the II and III trimester of pregnancy and during lactation the drug is used very carefully.
Particular caution should be observed in severe kidney and liver pathologies. In this situation, the solution for inhalation should be taken in a smaller dose, or between the doses of the agent, large intervals are maintained.
To date, medicine does not have accurate data on the use of the drug in the first 28 weeks of pregnancy. In the II and III trimesters, the use of medications should only be carried out with the permission of the doctor, after carefully weighing the ratio of the intended benefit of therapy to the mother and the potential risk to the fetus.
The use of a solution for inhalations during the breastfeeding of a child has also not been adequately studied. Therefore, the decision on the appropriateness of taking medications should be made by the attending physician, taking into account the risk to the child and the expected benefit for the mother.
When carrying out experiments on animals, it was established that Ambrohexal does not have a teratogenic effect (does not disturb the processes of embryogenesis), is reabsorbed from human milk.
Special indications when using
With extreme caution should be used in patients with a weakened cough reflex or disturbed mucociliary transport, since in this situation, inhalations can cause sputum congestion. Also during the period of treatment is not recommended to perform respiratory gymnastics. Patients suffering from bronchial asthma on the background of using the drug may increase cough.
Patients with impaired tolerance to fructose before proceeding to inhalations, it is necessary to consult with the attending physician.
Data on the impact on the ability to drive vehicles and manage various mechanisms is not available.
Interaction with other medicinal products
With simultaneous use of Ambrohexal injection for injections with antitussive agents that inhibit cough reflex, sputum stagnation may occur, leading to the development of sufficiently dangerous conditions. Therefore, such combinations must be selected with extreme caution.
With the combined use of Ambrohexal and antibacterial drugs ( amoxicillin , erythromycin, cefuroxime and doxycycline), there is a significant increase in the bronchial secretion of the concentration of etiotropic components.
Conditions for the sale of the medicinal product
Solution for inhalation Ambroghexal refers to drugs OTC.
Store in a dark place inaccessible to children, at a temperature not exceeding 25 ° C.
The solution for inhalation Ambrohexal is suitable for use for 4 years from the date of release. Do not use the product beyond the expiry date printed on the package.
Analogues of Ambrohexal
Prices for inhalation solution Ambroghexal
Ambrohexal solution for ingestion and inhalation 50ml - from 100r.